

Message

From: Allran, John [Allran.John@epa.gov]
Sent: 11/16/2021 2:19:35 PM
To: OPPT ECRAD RAB6 [OPPT_ECRAD_RAB6@epa.gov]
CC: Gillespie, Andrew [Gillespie.Andrew@epa.gov]; Merilis, Giorvanni [merilis.giorvanni@epa.gov]
Subject: TSCA Insider discusses new publication on phthalates
Attachments: Role of Epidemiology in Risk Assessment case study of five ortho-phthalates Mafini et al 2021.pdf

In case you did not see the Inside TSCA article on phthalates: <https://insideepa.com/tsca-news/report-urges-strict-health-limits-five-phthalates-under-tsca-evaluation>

I included as an attached file the publication the article references. The main thing I cleaned from it at first glance is the assertion that epidemiology studies on these phthalates indicate neurodevelopmental and endocrine risks at doses lower than the anti-androgenic rat phthalate syndrome effects from animal studies that form the basis for the POD in other recent risk assessments on phthalates. And the article emphasizes the importance of evaluating the phthalates as a class, implying a cumulative risk assessment.

John Allran

U.S. EPA | Office of Chemical Safety and Pollution Prevention
Existing Chemicals Risk Assessment Division
Assessment Branch 6
Research Triangle Park, NC
Office: (919) 541-4831